Overview

Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas

Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To investigate the clinical efficacy of certolizumab pegol for fistula closure in Crohn's disease subjects with active draining fistulas.
Phase:
Phase 3
Details
Lead Sponsor:
UCB Pharma
Treatments:
Certolizumab Pegol